XML 42 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
INCOME TAXES
12 Months Ended
Dec. 31, 2012
INCOME TAXES [Abstract]  
INCOME TAXES
NOTE 12 - INCOME TAXES

Income tax expense differs from the statutory amounts as follows:

   
2012
  
2011
 
        
Income taxes at U.S. statutory rate
 $(4,260,000) $(861,000)
State taxes
  -   17,000 
Current year reserve
  3,578,000   857,000 
Expenses not deductible
  682,000   4,000 
         
Total tax expense
 $-  $17,000 
 
Deferred taxes are provided for the temporary differences between the financial reporting bases and the tax bases of our assets and liabilities. The temporary differences that give rise to deferred tax assets were as follows:
 
   
December 31,
 
   
2012
  
2011
 
Deferred tax assets
      
Net operating loss carryforwards
 $64,147,000  $63,830,000 
General business credit carryforwards
  2,450,000   2,439,000 
State credits
  3,072,000   3,097,000 
Property and equipment
  57,000   46,000 
Stock options
  1,531,000   1,480,000 
Derivatives
  4,007,000   2,018,000 
Deferred revenue
  899,000   1,221,000 
Intangible assets
  517,000   415,000 
Accrued interest
  253,000   253,000 
Other
  230,000   231,000 
Gross deferred tax assets
  77,163,000   75,030,000 
Valuation allowance
  (77,163,000)   (75,030,000)
Net deferred taxes
 $-  $- 
 
At December 31, 2012, we had approximately $188,666,000 of net operating loss carryforwards and approximately $2,450,000 of general business credit carryforwards. These carryforwards expire as follows:
 
   
Net operating
  
General business
 
   
loss carryforwards
  
credit carryforwards
 
2012
 $-  $- 
2013
  -   - 
2014
  -   - 
2015
  -   - 
Thereafter
  188,666,000   2,450,000 
   $188,666,000  $2,450,000 
 
As a result of a merger on January 25, 1996, a change in control occurred for federal income tax purposes, which limits the utilization of pre-merger net operating loss carryforwards of approximately $3,100,000 to approximately $530,000 per year.
 
Additionally, we acquired MacroChem Corporation on February 25, 2009 and Somanta Pharmaceuticals, Inc. on January 4, 2008. Both corporations were loss companies at the time of the acquisition. Therefore, the net operating losses related to those acquisitions may be subject to annual limitations as provided by IRC Sec. 382.
 
We account for uncertain income tax positions in accordance with FASB ASC 740, Income Taxes. Interest costs and penalties related to income taxes are classified as interest expense and general and administrative costs, respectively, in our consolidated financial statements. For the years ended December 31, 2012 and 2011, we did not recognize any uncertain income tax positions or interest or penalty expense related to income taxes. It is determined not to be reasonably likely for the amounts of unrecognized tax benefits to significantly increase or decrease within the next 12 months. We are currently subject to a three year statute of limitations by major tax jurisdictions. We and our subsidiaries file income tax returns in the U.S. federal jurisdiction.